(Q42774095)

7 November 2017

Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin (English)

1 reference

7 November 2017

Ralston SH

1

1 reference

7 November 2017

Alzaid AA

series ordinal

2

1 reference

7 November 2017

Gardner MD

series ordinal

3

1 reference

7 November 2017

Boyle IT

series ordinal

4

1 reference

7 November 2017

language of work or name

English

0 references

publication date

1 June 1986

1 reference

7 November 2017

2

1 reference

based on heuristic

inferred from page(s)

published in

The BMJ

1 reference

7 November 2017

292

1 reference

7 November 2017

6535

1 reference

7 November 2017

1549-1550

1 reference

7 November 2017

Malignant hypercalcaemia

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340556

Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

27 May 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1340556

Relation between serum and urinary calcium with particular reference to parathyroid activity

27 May 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3087513

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3087513

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

1 reference

7 November 2017

PubMed publication ID

3087513

1 reference